Literature DB >> 15470492

TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.

V H J van der Velden1, M Brüggemann, P G Hoogeveen, M de Bie, P G Hart, T Raff, H Pfeifer, S Lüschen, T Szczepański, E R van Wering, M Kneba, J J M van Dongen.   

Abstract

Using the multiplex PCR tubes of the BIOMED-2 Concerted Action, TCRB gene rearrangements were detected in 35% of childhood (n=161) and adult (n=172) precursor-B-ALL patients (Vbeta-(Dbeta)-Jbeta in 25%; Dbeta-Jbeta in 15%). The presence of TCRB rearrangements showed a significant relation with age (highest frequency of 46% between 5 and 10 years of age) and the presence of TEL-AML1 transcripts, and was associated with relatively high frequencies of IGK-Kde, TCRG, and Vdelta2-Jalpha rearrangements. In 62 out of 65 patients with Southern blot-detected Vbeta-(Dbeta)-Jbeta and/or Dbeta-Jbeta rearrangements, at least one TCRB gene rearrangement was detected by PCR. Based on combined Southern blot and PCR analysis, oligoclonal TCRB gene rearrangements were observed in only 12% of patients. Analysis of paired diagnosis and relapse samples (n=26) showed that 20 out of 24 (83%) Vbeta-(Dbeta)-Jbeta rearrangements and eight out of 14 (57%) Dbeta-Jbeta rearrangements remained stable. Using real-time quantitative PCR, a quantitative range < or =10(-4) was obtained in 64% of TCRB gene rearrangements and in 86% of cases a sensitivity < or =10(-4) was obtained. In conclusion, TCRB gene rearrangements occur in 35% of precursor-B-ALL patients and are relatively stable and sensitive PCR targets for detection of minimal residual disease, particularly if this concerns complete Vbeta-(Dbeta)-Jbeta rearrangements.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470492     DOI: 10.1038/sj.leu.2403505

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies.

Authors:  Anna Gazzola; Claudia Mannu; Maura Rossi; Maria Antonella Laginestra; Maria Rosaria Sapienza; Fabio Fuligni; Maryam Etebari; Federica Melle; Elena Sabattini; Claudio Agostinelli; Francesco Bacci; Carlo Alberto Sagramoso Sacchetti; Stefano Aldo Pileri; Pier Paolo Piccaluga
Journal:  Ther Adv Hematol       Date:  2014-04

Review 2.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

3.  Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

Authors:  Aaron C Logan; Nikita Vashi; Malek Faham; Victoria Carlton; Katherine Kong; Ismael Buño; Jianbiao Zheng; Martin Moorhead; Mark Klinger; Bing Zhang; Amna Waqar; James L Zehnder; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

Review 4.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

5.  PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Authors:  Yozo Nakazawa; Leslie E Huye; Vita S Salsman; Ann M Leen; Nabil Ahmed; Lisa Rollins; Gianpietro Dotti; Stephen M Gottschalk; Matthew H Wilson; Cliona M Rooney
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

Review 6.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 7.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

Review 8.  Status of minimal residual disease testing in childhood haematological malignancies.

Authors:  Dario Campana
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

9.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

Review 10.  Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells.

Authors:  Michaela Kotrova; Nikos Darzentas; Christiane Pott; Claudia D Baldus; Monika Brüggemann
Journal:  Genes (Basel)       Date:  2021-06-27       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.